Death from Liver Failure despite Lamivudine Prophylaxis during R-CHOP Chemotherapy due to Rapid Emergence M204 Mutations

Background. Rapid and early emergence of clinically significant LAM resistance is thought to be unlikely during the first year of treatment, and as a result LAM is thought to be a reasonable choice as a first line agent for prophylaxis during chemotherapy. Aim. To report fatal HBV reactivation despi...

Descripción completa

Detalles Bibliográficos
Autores principales: Win, Lay Lay, Powis, Jeff, Shah, Hemant, Feld, Jordan J., Wong, David K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2013
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4208428/
https://www.ncbi.nlm.nih.gov/pubmed/25374716
http://dx.doi.org/10.1155/2013/454897

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4208428/
https://www.ncbi.nlm.nih.gov/pubmed/25374716
http://dx.doi.org/10.1155/2013/454897

Ejemplares similares